# ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 P&L / Income Statement

- Company: ACADIA PHARMACEUTICALS INC. (ACAD)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-333243
- Page: https://plicit.ai/financials/acad/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/acad-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 307,959,000 US dollars
- **Cost of product sales**: 28,316,000 US dollars
- **Gross profit (calculated)**: 279,643,000 US dollars
- **Operating expenses (calculated)**: 241,807,000 US dollars
- **Income from operations**: 37,836,000 US dollars
- **Other income (expense), net (calculated)**: 8,637,000 US dollars
- **Income before income taxes**: 46,473,000 US dollars
- **Income tax expense**: 14,973,000 US dollars
- **Net loss**: 31,500,000 US dollars
- **Reportable Segment - DAYBUE products**: 124,827,000 US dollars
- **Reportable Segment - NUPLAZID**: 183,132,000 US dollars
- **Research and development**: 81,555,000 US dollars
- **Selling, general and administrative**: 160,252,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Customer

- Page: https://plicit.ai/financials/acad/fy2026-q2-income-statement/revenue-by-customer
- Chart image: https://plicit.ai/charts/acad-fy2026-q2-revenue-by-customer-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Customer. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 307,959,000 US dollars
- **Cost of product sales**: 28,316,000 US dollars
- **Gross profit (calculated)**: 279,643,000 US dollars
- **Operating expenses (calculated)**: 241,807,000 US dollars
- **Income from operations**: 37,836,000 US dollars
- **Other income (expense), net (calculated)**: 8,637,000 US dollars
- **Income before income taxes**: 46,473,000 US dollars
- **Income tax expense**: 14,973,000 US dollars
- **Net loss**: 31,500,000 US dollars
- **NUPLAZID**: 183,132,000 US dollars
- **DAYBUE products**: 124,827,000 US dollars
- **Research and development**: 81,555,000 US dollars
- **Selling, general and administrative**: 160,252,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.